TrialClinical interventions in aging2014

Long-term safety and tolerability of saxagliptin add-on therapy in older patients (aged ≥ 65 years) with type 2 diabetes.

Nayyar Iqbal et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.